Business
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights
First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025 Strengthened Leadership Team with the Appointment of Tony Gibney as Chief Financial and Business Officer BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial res
About this update from Aura Biosciences, Inc.
[{"type":"image","alt":"Aura Biosciences, Inc.","displaySize":"","headline":null,"caption":"Aura Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":76,"url":"https://media.zenfs.com/en/globenewswire.com/2592eb91327180eb73f99563eef568ed"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gFIc2.J2rzI4RhAQ9QXMDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2592eb91327180eb73f99563eef568ed","width":300,"height":76}},"lazy":false},{"type":"text","content":"First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025","length":162,"tagName":"p"},{"type":"text","content":"Strengthened Leadership Team with the Appointment of Tony Gibney as Chief Financial and Business Officer","length":104,"tagName":"p"},{"type":"text","content":"BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the first quarter ended March 31, 2025, and provided recent business highlights.","length":321,"tagName":"p"},{"type":"text","content":"“Aura has started 2025 with strong momentum, making meaningful strides across both our ocular and urologic oncology programs,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura. “Our global Phase 3 CoMpass trial in early-stage choroidal melanoma continues to advance, and we enrolled the first patient in our multi-dose Phase 1b/2 trial in NMIBC. At Aura, we remain deeply focused on transforming the treatment landscape in ocular and urologic cancers—two areas where patients urgently need innovative therapies.”","length":530,"tagName":"p"},{"type":"text","content":"Recent Pipeline Developments ","length":28,"tagName":"p"},{"type":"text","content":"Early-Stage Choroidal Melanoma","length":30,"tagName":"p"},{"type":"text","content":"Update on Ongoing Phase 3 CoMpass Trial: CoMpass is the first registration-enabling study in early-stage choroidal melanoma. The study is a global, Phase 3, randomized trial evaluating bel-sar treatment against a sham control arm and includes an enrichment strategy to enroll approximately 100 patients with documented tumor g...